MedPath

AustarPharma, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 4:1

Drug Approvals

6

FDA:5
SFDA:1

Drug Approvals

CARBAMAZEPINE ER

Approval Date
Jan 3, 2024
FDA

Solifenacin Succinate

Approval Date
Jan 3, 2024
FDA

Fenofibrate

Approval Date
Jan 24, 2023
FDA

Methocarbamol

Approval Date
Jan 13, 2022
FDA

Fenofibrate

Approval Date
Dec 23, 2019
FDA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 4
1 (100.0%)

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

Phase 4
Completed
Conditions
Bioequivalence
Interventions
First Posted Date
2020-09-02
Last Posted Date
2023-02-02
Lead Sponsor
Austarpharma, LLC
Target Recruit Count
96
Registration Number
NCT04536415
Locations
🇺🇸

Austarpharma Llc, Edison, New Jersey, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.